Skip to content
World Firm Ledger
Directory

1v1 Institutional Counterparty Comparison

China Galaxy vs InBioGen: Regulation, 6D Ratings & Safety Audit

Deterministic head-to-head benchmarking of China Galaxy (China Galaxy International Financial Holdings Limited) and InBioGen (InBioGen Co Ltd) across primary regulatory filings, statutory Tier-1 authorisations, 6-Dimension compliance scores, execution software, and warning exposure.

Coverage: Selected financial institution records: Singapore, Asia-Pacific, the Middle East and emerging markets

DETERMINISTIC QUANTITATIVE VERDICTCanonical Pair: china-galaxy-vs-inbiogen

China Galaxy outranks InBioGen by +1.8 pts in composite 6D scoring (6.8 vs 5.0)

On supervisory breadth, China Galaxy holds 1 active regulated licence(s) (0 Tier-1) out of 1 total filings and 0 warning count(s), whereas InBioGen holds 0 active regulated licence(s) (0 Tier-1) out of 0 total filings and 0 warning count(s). Allocators should inspect the individual licence numbers and contracting legal entities below before onboarding.

6-Dimension Quantitative Scorecard Comparison

Head-to-head breakdown across all 6 proprietary evaluation dimensions (0.0–10.0 scale).

Evaluation DimensionMethodology WeightChina GalaxyInBioGenScore DeltaDimension Leader
Overall Composite 6D Score100% Composite6.85.0+1.8China Galaxy
Regulatory & Licensing Integrity (riskScore)30% Weight6.85.0+1.8China Galaxy
Execution & Software Infrastructure (industryScore)20% Weight4.03.0+1.0China Galaxy
User Reputation & Complaint Telemetry (userScore)20% Weight0.00.00.0Statistical Tie
Institutional Brand Longevity (brandScore)15% Weight6.85.0+1.8China Galaxy
Global Market Influence & Footprint (influenceScore)15% Weight6.85.0+1.8China Galaxy

Visual Architecture Benchmark: China Galaxy vs InBioGen

Vector comparison exhibit generated from live supervisory snapshot metrics.

1v1 Institutional Counterparty Benchmark: China Galaxy vs InBioGen
Exhibit: Side-by-side regulatory and 6D quantitative comparison between China Galaxy and InBioGen.

Regulatory Standing, Entity & Platform Comparison

Structural comparison of supervisory authorisations, domicile, execution terminals, and risk telemetry.

Audit AttributeChina GalaxyInBioGen
Primary Legal NameChina Galaxy International Financial Holdings LimitedInBioGen Co Ltd
Source Risk ClassificationRisk level not suppliedRisk level not supplied
Active Regulated / Total Filings1 regulated / 1 total (0 Tier-1)0 regulated / 0 total (0 Tier-1)
Recorded Certificate NumbersNone on file
Registered Domicile / Address20/F, Wing On Centre, 111 Connaught Road Central, Sheung Wan, Hong Kong Flat 1, 36/F, COSCO Tower, Queen's Road Central, Hong Kong Flat 1, 36/F, COSCO Tower, Queen's Road Central, Hong Kong 8/F, May May Building, Nos.683-685 Nathan Road, Kowloon, Hong Kong14F, 61, Digital-ro 26-gil, Guro-gu, Seoul, Republic of Korea
Offered Asset Classes & ServicesSecurities brokerage (including stocks, funds, bonds, derivatives and futures), securities investment consulting, financial consulting for securities trading and securities investment, securities underwriting and sponsorship, securities proprietary trading, and securities asset management.Multi-asset financial services
Execution Software & TerminalsProprietary / Web PlatformProprietary / Web Platform
Supported Client LanguagesChinese (Simplified), Chinese (Traditional), EnglishEnglish
Warning / Exposure Count0 recorded warning(s)0 recorded warning(s)

Frequently Asked Questions: China Galaxy vs InBioGen

Deterministic counterparty comparison answers derived from supervisory records.

Which institution has stronger regulatory oversight: China Galaxy or InBioGen?

China Galaxy holds more active regulated filings (1 vs 0). Specifically, China Galaxy maintains 1 total recorded filing(s) (SFC) with 0 warning flag(s), whereas InBioGen maintains 0 recorded filing(s) (none on file) with 0 warning flag(s). Always confirm the specific subsidiary onboarding your account on the official regulator register.

How do the 6D quantitative compliance scores compare between China Galaxy and InBioGen?

In World Firm Ledger's 6-Dimension scoring matrix (0.0–10.0 scale), China Galaxy records an Overall Score of 6.8 (Risk & Licensing: 6.8, Brand: 6.8, Market Influence: 6.8, User Reputation: 0.0, Execution & Software: 4.0), compared with InBioGen at 5.0 Overall (Risk & Licensing: 5.0, Brand: 5.0, Market Influence: 5.0, User Reputation: 0.0, Execution & Software: 3.0).

How do China Galaxy and InBioGen differ in trading platforms and asset classes?

China Galaxy lists Securities brokerage (including stocks, funds, bonds, derivatives and futures), securities investment consulting, financial consulting for securities trading and securities investment, securities underwriting and sponsorship, securities proprietary trading, and securities asset management. with execution software [proprietary/web execution], while InBioGen lists general financial services with execution software [proprietary/web execution]. Counterparties should verify FIX/API connectivity, server routing topology, and negative balance protection per entity.

Which counterparty carries lower regulatory warning and complaint exposure: China Galaxy or InBioGen?

China Galaxy carries a "Risk level not supplied" classification with 0 warning/exposure count(s) and 0 user comment(s), while InBioGen carries a "Risk level not supplied" classification with 0 warning/exposure count(s) and 0 user comment(s).

Structured against supervisory register snapshots and public regulatory filings. Verify your contracting legal entity and current authorisation status directly on the issuing regulator’s official register before transacting.

China Galaxy vs InBioGen (2026) — Regulation, 6D Score, Safety & Fee Comparison | World Firm Ledger